Aptamers Market worth $342 million by 2026 – Industry-Specific Opportunities and Trends Affecting the Growth

MarketsandMarkets™ Research Report Opinion on Revenue Impact?

the aptamers market Valued at US$151 million in 2021 and expected to reach US$342 million by 2026, at a compound annual growth rate of 17.7% over the forecast period

Factors responsible for growth and in-depth analysis?

The growth of the aptamers technology market has been attributed to factors such as an increase in the number of clinical trials to develop aptamer-based therapies, increased awareness of the advantages of aptamers over antibodies, increased investment in pharmaceutical research and development, and an increase in the prevalence of chronic and rare diseases to increase the demand for aptamer-based therapies and diagnostics. Growth in venture capital funding for aptamer research and increased collaboration with research institutes and pharmaceutical companies is also expected to provide a wide range of growth opportunities for market players.

On the other hand, low market acceptance compared to antibodies is likely to restrict market growth while lack of skilled and trained professionals may challenge market growth to a certain extent.

Download PDF brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1167

aptamers market

Leading Key Players and Analysis:

Some of the notable players operating in this market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc. (US), Aptamer Sciences, Inc. (South Korea) and Aptagen, LLC (US).

Aptamer Group (UK) Developed advanced Optimer technology, which is used to bring aptamer based solutions to market. This unique technology has enabled the company to strengthen its position in the market. The company is focused on expanding its reach into diagnostic and therapeutic applications. The company develops Optimer therapies for the treatment of spinal cord cancer, kidney disease and leukemia. In the past three years, the company has focused on collaborations and agreements to expand its geographic reach and Optimer technology capabilities in treatments. It recently collaborated with several diagnostic and pharmaceutical companies to determine the potential for use of aptamers as therapeutic and diagnostic agents. This has enabled the company to increase its foothold in the aptamers technology market.

Raptamer Discovery Group (USA) Focus on developing the next generation of aptamers for diagnostic and therapeutic applications. The company uses Raptamer technology to develop these aptamers. The company has a strong client base including pharmaceutical companies and academic and research institutes all over the world. The company has received funding to develop the aptamer-based therapy from various government institutes such as the National Aeronautics and Space Agency (NASA) and the National Institutes of Health (NIH). This provided the company with a gateway to expand its horizon in treatment development applications.

Geographical analysis in detail?

The global aptamer market is divided into five main regions – North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2020, North America captured the largest share of this market. The largest share of North America is attributed to the availability of funds for the development of innovative technologies, the presence of significant players in the market, and the increased cooperation between companies. The Asia Pacific market is estimated to register the highest compound annual growth rate (CAGR) during the forecast period. This is attributed to increased research and development activities on aptamers, development of aptamer-based products, and an increased focus on drug discovery and development.

Request form pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=1167

Industry segmentation:

“Therapeutics development segment will continue to dominate the aptamers market during the forecast period”

Based on the application, the aptamers market is segmented into treatment development, research and development, diagnostics, and other applications. In 2020, the therapeutic development segment has dominated the market due to the increasing number of clinical trials evaluating aptamers for new treatments and collaboration between aptamer companies and prominent pharmaceutical and biotechnology companies. The diagnostic segment is expected to grow at the highest compound annual growth rate (CAGR) due to the increased prevalence of chronic diseases and the development of new diagnostic kits for the detection of cancer and other diseases.

Pharmaceutical and biotechnology companies are the largest end users of aptamers.

Based on the end user, the global aptamers market is segmented into pharmaceutical companies, biotechnology companies, academic and government research institutes, contract research organizations, and other end users. In 2020, pharmaceutical and biotechnology companies dominated the market due to the increasing number of market players offering customized aptamers for use in developing therapeutics and increasing research and development expenditures. The diagnostic segment will register the highest compound annual growth rate (CAGR) during the forecast period due to the development of cancer and infectious disease diagnostic tools.

Talk to the analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1167

.

Leave a Comment